These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10863974)

  • 21. Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.
    Keating GM
    Clin Drug Investig; 2014 Dec; 34(12):895-904. PubMed ID: 25351934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
    Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
    Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
    Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
    Richardson PG; Soiffer RJ; Antin JH; Uno H; Jin Z; Kurtzberg J; Martin PL; Steinbach G; Murray KF; Vogelsang GB; Chen AR; Krishnan A; Kernan NA; Avigan DE; Spitzer TR; Shulman HM; Di Salvo DN; Revta C; Warren D; Momtaz P; Bradwin G; Wei LJ; Iacobelli M; McDonald GB; Guinan EC
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):1005-17. PubMed ID: 20167278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
    Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management.
    Al Jefri AH; Abujazar H; Al-Ahmari A; Al Rawas A; Al Zahrani Z; Alhejazi A; Bekadja MA; Ibrahim A; Lahoucine M; Ousia S; Bazarbachi A
    Bone Marrow Transplant; 2017 Apr; 52(4):588-591. PubMed ID: 27892944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of defibrotide in blood and marrow transplantation.
    Richardson PG; Carreras E; Iacobelli M; Nejadnik B
    Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.
    Ho VT; Linden E; Revta C; Richardson PG
    Semin Thromb Hemost; 2007 Jun; 33(4):373-88. PubMed ID: 17525895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment.
    Sonneveld P; Laméris JS; Cornelissen J; Ogilvie A; Löwenberg B
    Bone Marrow Transplant; 1998 Apr; 21(7):731-4. PubMed ID: 9578316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant.
    Veenstra DL; Guzauskas GF; Villa KF; Boudreau DM
    J Med Econ; 2017 May; 20(5):453-463. PubMed ID: 28008770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
    Corbacioglu S; Cesaro S; Faraci M; Valteau-Couanet D; Gruhn B; Rovelli A; Boelens JJ; Hewitt A; Schrum J; Schulz AS; Müller I; Stein J; Wynn R; Greil J; Sykora KW; Matthes-Martin S; Führer M; O'Meara A; Toporski J; Sedlacek P; Schlegel PG; Ehlert K; Fasth A; Winiarski J; Arvidson J; Mauz-Körholz C; Ozsahin H; Schrauder A; Bader P; Massaro J; D'Agostino R; Hoyle M; Iacobelli M; Debatin KM; Peters C; Dini G
    Lancet; 2012 Apr; 379(9823):1301-9. PubMed ID: 22364685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Veno occlusive disease: update on clinical management.
    Senzolo M; Germani G; Cholongitas E; Burra P; Burroughs AK
    World J Gastroenterol; 2007 Aug; 13(29):3918-24. PubMed ID: 17663504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients.
    Myers KC; Lawrence J; Marsh RA; Davies SM; Jodele S
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):500-3. PubMed ID: 23211838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic veno-occlusive disease after bone marrow transplant.
    Carreras E; Grañena A; Rozman C
    Blood Rev; 1993 Mar; 7(1):43-51. PubMed ID: 8467232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide.
    Corbacioglu S; Hönig M; Lahr G; Stöhr S; Berry G; Friedrich W; Schulz AS
    Bone Marrow Transplant; 2006 Oct; 38(8):547-53. PubMed ID: 16953210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic veno-occlusive disease after tranexamic acid administration in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Mori T; Aisa Y; Shimizu T; Yamazaki R; Mihara A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Am J Hematol; 2007 Sep; 82(9):838-9. PubMed ID: 17506069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High Variability in the Reported Management of Hepatic Veno-Occlusive Disease in Children after Hematopoietic Stem Cell Transplantation.
    Skeens MA; McArthur J; Cheifetz IM; Duncan C; Randolph AG; Stanek J; Lehman L; Bajwa R;
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1823-1828. PubMed ID: 27496218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD).
    Kulkarni S; Rodriguez M; Lafuente A; Mateos P; Mehta J; Singhal S; Saso R; Tait D; Treleaven JG; Powles RL
    Bone Marrow Transplant; 1999 Apr; 23(8):803-7. PubMed ID: 10231143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
    Dong M; Lin Q; Wu XY
    Ai Zheng; 2008 Jun; 27(6):646-9. PubMed ID: 18570742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.